LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

98%

334 / 352 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. veebr 2026, 23:53 UTC

Kuumad aktsiad

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27. veebr 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

27. veebr 2026, 17:55 UTC

Kuumad aktsiad

Toronto Stocks Decline, But Remain On Track for Weekly Gains

27. veebr 2026, 23:46 UTC

Omandamised, ülevõtmised, äriostud

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27. veebr 2026, 23:33 UTC

Omandamised, ülevõtmised, äriostud

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27. veebr 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

27. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27. veebr 2026, 21:30 UTC

Tulu

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27. veebr 2026, 21:30 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27. veebr 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27. veebr 2026, 21:17 UTC

Tulu

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27. veebr 2026, 21:10 UTC

Omandamised, ülevõtmised, äriostud

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27. veebr 2026, 21:09 UTC

Omandamised, ülevõtmised, äriostud

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27. veebr 2026, 21:00 UTC

Tulu

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27. veebr 2026, 20:31 UTC

Omandamised, ülevõtmised, äriostud

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27. veebr 2026, 20:24 UTC

Market Talk

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27. veebr 2026, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27. veebr 2026, 20:12 UTC

Market Talk

Nike Seen With Further Challenges in China -- Market Talk

27. veebr 2026, 19:44 UTC

Market Talk

Gold Caps Historic Month -- Market Talk

27. veebr 2026, 19:39 UTC

Tulu

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27. veebr 2026, 19:38 UTC

Tulu

Earnings Could Push the Stock Market Higher. Too Bad About Everything Else. -- Barrons.com

27. veebr 2026, 18:53 UTC

Omandamised, ülevõtmised, äriostud

Largest U.S. Pension Takes Stake in a Hot Semi Stock, Buys More Nvidia and IonQ -- Barrons.com

27. veebr 2026, 18:45 UTC

Tulu

Quantum Computing Is No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

27. veebr 2026, 18:45 UTC

Market Talk

Bitcoin Stays Vulnerable in Choppy Geopolitical Situation -- Market Talk

27. veebr 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

27. veebr 2026, 17:07 UTC

Tulu

Pemex Cuts 4Q Loss As Operating Results Improve

27. veebr 2026, 17:00 UTC

Market Talk

Corn Rides Oil Momentum Higher -- Market Talk

27. veebr 2026, 16:31 UTC

Market Talk

Canadian Economy Shows Resilience -- Market Talk

27. veebr 2026, 16:17 UTC

Market Talk

Canada Economy is Struggling But More Rate Cuts Still a Long Shot -- Market Talk

27. veebr 2026, 15:49 UTC

Tulu

Quantum Computing No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

334 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.